Drug intelligence / Profile preview

nimesulide + paracetamol (Abigail Healthcare)

Development stage
Unknown
Lead developer
Abigail Healthcare
Modality
Small Molecules
Administration
Oral
01

Overview

Homonim is an approved fixed-dose combination analgesic and antipyretic tablet marketed by Abigail Care Pharmaceutical (under its Homogreen division) in India. Each tablet contains nimesulide (100 mg) and paracetamol (325 mg). Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) that acts as a selective competitive inhibitor of cyclooxygenase-2 (COX-2), thereby blocking the synthesis of prostaglandins responsible for pain, inflammation, and fever. Paracetamol (acetaminophen) is a widely used analgesic and antipyretic that acts primarily on the central nervous system to block pain impulse generation and reduce fever. Together, this combination provides rapid and synergistic relief from acute pain, fever, and inflammation associated with conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, headache, toothache, menstrual pain, muscle pain, and postoperative pain.

Brand names
BestogesicDolamideEmsulide PHomonimNicloc-PNimcure-PNimica PlusNimeson PNimprex-PNise-P
Other names
Hom onimnimesulide + acetaminophennimesulide and paracetamolnimesulide/paracetamolparacetamol + nimesulide
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PRKCE (Protein Kinase C epsilon)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on nimesulide + paracetamol (Abigail Healthcare).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nimesulide + paracetamol (Abigail Healthcare).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call